GTI-2040

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameGTI-2040
Drug Alias NameGTI-2040LOR-2040NSC-722929
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA inhibitors
TargetsDNARibonucleotide reductase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAptose
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteAptose Biosciences IncUniversity Health Network (Uhn)
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[14] 

Other Information

ATC CodeN/A
Related LinksDrugBank